Outcomes and Timing of Bedside Percutaneous Tracheostomy of COVID-19 Patients over a Year in the Intensive Care Unit
BACKGROUND: The benefits and timing of percutaneous dilatational tracheostomy (PDT) in Intensive Care Unit (ICU) COVID-19 patients are still controversial. PDT is considered a high-risk procedure for the transmission of SARS-CoV-2 to healthcare workers (HCWs). The present study analyzed the optimal timing of PDT, the clinical outcomes of patients undergoing PDT, and the safety of HCWs performing PDT.
METHODS: Of the 133 COVID-19 patients who underwent PDT in our ICU from 1 April 2020 to 31 March 2021, 13 patients were excluded, and 120 patients were enrolled. A trained medical team was dedicated to the PDT procedure. Demographic, clinical history, and outcome data were collected. Patients who underwent PDT were stratified into two groups: an early group (PDT ≤ 12 days after orotracheal intubation (OTI) and a late group (>12 days after OTI). An HCW surveillance program was also performed.
RESULTS: The early group included 61 patients and the late group included 59 patients. The early group patients had a shorter ICU length of stay and fewer days of mechanical ventilation than the late group (p < 0.001). On day 7 after tracheostomy, early group patients required fewer intravenous anesthetic drugs and experienced an improvement of the ventilation parameters PaO2/FiO2 ratio, PEEP, and FiO2 (p < 0.001). No difference in the case fatality ratio between the two groups was observed. No SARS-CoV-2 infections were reported in the HCWs performing the PDTs.
CONCLUSIONS: PDT was safe and effective for COVID-19 patients since it improved respiratory support parameters, reduced ICU length of stay and duration of mechanical ventilation, and optimized the weaning process. The procedure was safe for all HCWs involved in the dedicated medical team. The development of standardized early PDT protocols should be implemented, and PDT could be considered a first-line approach in ICU COVID-19 patients requiring prolonged mechanical ventilation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 10(2021), 15 vom: 28. Juli |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 10.08.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm10153335 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329063847 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329063847 | ||
| 003 | DE-627 | ||
| 005 | 20231225204305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm10153335 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM329063847 | ||
| 035 | |a (NLM)34362118 | ||
| 035 | |a (PII)3335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tetaj, Nardi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes and Timing of Bedside Percutaneous Tracheostomy of COVID-19 Patients over a Year in the Intensive Care Unit |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: The benefits and timing of percutaneous dilatational tracheostomy (PDT) in Intensive Care Unit (ICU) COVID-19 patients are still controversial. PDT is considered a high-risk procedure for the transmission of SARS-CoV-2 to healthcare workers (HCWs). The present study analyzed the optimal timing of PDT, the clinical outcomes of patients undergoing PDT, and the safety of HCWs performing PDT | ||
| 520 | |a METHODS: Of the 133 COVID-19 patients who underwent PDT in our ICU from 1 April 2020 to 31 March 2021, 13 patients were excluded, and 120 patients were enrolled. A trained medical team was dedicated to the PDT procedure. Demographic, clinical history, and outcome data were collected. Patients who underwent PDT were stratified into two groups: an early group (PDT ≤ 12 days after orotracheal intubation (OTI) and a late group (>12 days after OTI). An HCW surveillance program was also performed | ||
| 520 | |a RESULTS: The early group included 61 patients and the late group included 59 patients. The early group patients had a shorter ICU length of stay and fewer days of mechanical ventilation than the late group (p < 0.001). On day 7 after tracheostomy, early group patients required fewer intravenous anesthetic drugs and experienced an improvement of the ventilation parameters PaO2/FiO2 ratio, PEEP, and FiO2 (p < 0.001). No difference in the case fatality ratio between the two groups was observed. No SARS-CoV-2 infections were reported in the HCWs performing the PDTs | ||
| 520 | |a CONCLUSIONS: PDT was safe and effective for COVID-19 patients since it improved respiratory support parameters, reduced ICU length of stay and duration of mechanical ventilation, and optimized the weaning process. The procedure was safe for all HCWs involved in the dedicated medical team. The development of standardized early PDT protocols should be implemented, and PDT could be considered a first-line approach in ICU COVID-19 patients requiring prolonged mechanical ventilation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ICU length of stay | |
| 650 | 4 | |a ICU stay | |
| 650 | 4 | |a early tracheostomy | |
| 650 | 4 | |a healthcare workers | |
| 650 | 4 | |a intensive care unit | |
| 650 | 4 | |a late tracheostomy | |
| 650 | 4 | |a mechanical ventilation | |
| 650 | 4 | |a percutaneous tracheostomy | |
| 700 | 1 | |a Maritti, Micaela |e verfasserin |4 aut | |
| 700 | 1 | |a Stazi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Marini, Maria Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Centanni, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Garotto, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Caravella, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Dantimi, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Fusetti, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Santagata, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Macchione, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a De Angelis, Giada |e verfasserin |4 aut | |
| 700 | 1 | |a Giansante, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Busso, Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Di Lorenzo, Rachele |e verfasserin |4 aut | |
| 700 | 1 | |a Scarcia, Silvana |e verfasserin |4 aut | |
| 700 | 1 | |a Carucci, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Cabas, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gaviano, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Petrosillo, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a D'Offizi, Gianpiero |e verfasserin |4 aut | |
| 700 | 1 | |a Ianniello, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Campioni, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Vaia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Marchioni, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Icu Covid-Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 10(2021), 15 vom: 28. Juli |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:15 |g day:28 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm10153335 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 15 |b 28 |c 07 | ||